Ann: Appendix 4C - quarterly, page-20

First 20 Last

Mofra

364 Posts.

29/04/21

13:37

Post #: 52813040

Originally posted by TommyTrader: ↑
Assuming all costs stay as they are and they grow at 37% cases per quarter with revenue growth of 30%, They will be cashflow positive FY 22 Q4.

Column 1 Column 2 Column 3 Column 4 Column 5 Column 6
1 30% 37%
2 Quarter Revenue Cases Gross Prof Costs Net Prof
3
4 FY 21 Q2 $712,000.00 42252 $16.85
5 FY 21 Q3 $768,000.00 61939 $12.40 $2,200,000.00 -$1,432,000.00
6 FY 21 Q4 $998,400.00 84856.43 $11.77 $2,200,000.00 -$1,201,600.00
7 FY 22 Q1 $1,297,920.00 112010.4876 $11.59 $2,200,000.00 -$902,080.00
8 FY 22 Q2 $1,687,296.00 147853.8436 $11.41 $2,200,000.00 -$512,704.00
9 FY 22 Q3 $2,193,484.80 195167.0736 $11.24 $2,200,000.00 -$6,515.20
10
11 ASSUMING NO CHANGE
HOWEVER,

-Costs will increase
-New B2B structure will add revenue stream
-Ebay / Vivino also add new streams

This is very rough but gives an idea of where they are heading IF and only IF we see a change in their next quarterly regarding COSTS / REVENUES.

Much talk about Economies of Scale today; however they are not achieving these at this time, in fact quite the contrary from the last 4c. Lets hope they have a fair few one off costs within this quarter so the Costs dont look so miserable.

Once again I will get mocked for actually trying to provide some facts of the direction, but hey got to see both sides of the glass right...
Expand
Nice to see those figures so good work, although I don't believe there will be steady linear style growth given the seasonal nature of the industry.

Jan-Feb 2022 may show a reasonable increase on the Q1 figures just posted but by sheer virtue of the end of year period I'd expect a spike up in Q4 2021 then a reduction again Q1 2022.

DW8 Price at posting: 15.0¢ Sentiment: Buy Disclosure: Held

3 Upvote

0 Great analysis

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 13 more messages in this thread...

First 20 Last

Add KDY (ASX) to my watchlist

(20min delay)
Last 2.7¢		Change 0.000(0.00%)		Mkt cap ! $3.834M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: Appendix 4C - quarterly, page-20

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Featured News

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
1		30%	37%
2	Quarter	Revenue	Cases	Gross Prof	Costs	Net Prof
3
4	FY 21 Q2	$712,000.00	42252	$16.85
5	FY 21 Q3	$768,000.00	61939	$12.40	$2,200,000.00	-$1,432,000.00
6	FY 21 Q4	$998,400.00	84856.43	$11.77	$2,200,000.00	-$1,201,600.00
7	FY 22 Q1	$1,297,920.00	112010.4876	$11.59	$2,200,000.00	-$902,080.00
8	FY 22 Q2	$1,687,296.00	147853.8436	$11.41	$2,200,000.00	-$512,704.00
9	FY 22 Q3	$2,193,484.80	195167.0736	$11.24	$2,200,000.00	-$6,515.20
10
11					ASSUMING NO CHANGE

Ann: Appendix 4C - quarterly, page-20

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Featured News